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INTRODUCTION Nanoparticles may serve as a promising means to deliver novel
therapeutics to the myocardium following myocardial infarction. We assessed
whether lipid-based liposomal nanoparticles speciﬁcally target injured myocardium
following intravenous injection.
METHODS CD1 male mice that underwent LAD ligation surgery with 45 minutes of
ischemia followed by reperfusion (I/R) and then received tail-vein injection 24 hours
following surgery with either Gd-DTPA labeled, ﬂuorescent NBD-labeled liposomes
(n¼7) or a saline vehicle control (n¼7). The hearts were harvested 24 hours later and
underwent T1 and T2-weighted ex vivo MR imaging using a 7 Tesla Bruker magnet.
The hearts were the sectioned for immunohistochemistry and also optical ﬂuorescent
imaging using an IVIS imaging system.
RESULTS The mean size of the liposomes was 100 nm by dynamic light scattering.
T1-weighted imaging demonstrated a signiﬁcant increase in signal intensity in the
LAD territory vs the posterior wall with liposomes compared with control (41 10%
vs 9 2%, p¼0.009). Optical imaging demonstrated signiﬁcant increase in the LAD
territory vs the posterior wall for animals that received liposomes compared with
those that received control (16331% vs 1314%, p¼0.001). The Figure shows T1-
weighted MR images and optical images below. Fluorescent microscopy demon-
strated the presence of green ﬂuorescence consistent with NBD-labeled liposomes
within the infarct area of hearts from mice that received liposomes while there
was no green ﬂuorescence in the hearts of mice that received injection of saline
control.
CONCLUSIONS Following a murine model of MI, liposomes trafﬁc to the heart and
preferentially home to regions of myocardial injury. These liposomes can be loaded
with therapeutic agents to deliver novel agents directly to regions of myocardial
injury.TECHNOLOGYBIODEGRADABLE POLYMERS
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BACKGROUND A conﬂuent endothelium is needed to reduce thrombosis in vascular
grafts, including EVAR stent-grafts. A pilot study was designed to assess the tissue
formation and cellular response to an endovascular stent-graft containing a bio-
absorbable graft material designed to treat aneurysms through endovascular tissue
regeneration. The objective of the study was to determine the in vivo response of the
graft material in an AAA model.
METHODS A peritoneal patch was used to form an AAA in swine for 2 weeks then
treated with the bioabsorbable stent-graft (n¼7). The stent-graft consisted of a syn-
thetic polymer graft material sutured to a stent (Megalink, Guidant, USA). The stent-
graft was delivered endovascularly using an 11F sheath with a dilation catheter
(Powerﬂex P3, Cordis, USA). After treatment for 28 days, the animals were sacriﬁced
and the tissue was examined through both gross and microscopic histology to
determine the presence of endothelial cells (CD-31 antibody), smooth muscle cells
(SM a-actin antibody), collagen (Masson’s Trichrome) and any adverse tissue re-
sponses (H&E). Physical attachment of the graft to the vessel and gross appearance of
the lumen surface were also noted.
RESULTS The stent-grafts placed endovascularly demonstrated no evidence of blood
ﬂow into the aneurysmal sac upon deployment, based on angiography and ultrasound
imaging. During the course of the study, no endoleaks were observed in the treated
animals. Upon gross examination after sacriﬁce at 28 days, the graft material
appeared well adhered to the aorta with a shiny, white appearance on the lumen
surface. No evidence of thrombi was noted. The graft demonstrated a conﬂuent
endothelial lining as evidenced by histologic staining for CD-31 antibody which
positively stained a single layer of cells on the lumen surface. The new endothelium
was supported by a thin neointima consisting of collagen. In addition, the SM a-actin
antibody stain indicated the presence of smooth muscle cells on the abluminal
portion of the graft with cells penetrating the porous graft material. No signiﬁcant
adverse tissue response was noted. The graft material was integrated with the vessel
wall and grossly intact without any defects or degradation.
CONCLUSIONS A stent-graft containing a bioabsorbable graft material was success-
fully deployed endovascularly in a surgical swine model. The results of our pilot
study suggest that aneurysms may be treated using an appropriate bioabsorbable
material for endovascular tissue regeneration.BIODEGRADABLE SCAFFOLDS
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AIMS BMS and DES overlap is associated with impaired clinical outcomes at long-
term follow-up, whereas data on the impact of overlap with overlapping everolimus-
eluting bioresorbable vascular scaffold (Absorb BVS) are scant. We report the
procedural and mid-term clinical outcomes in a cohort of patients having at least one
vessel treated with 2 overlapped Absorb BVS.
